

Revision date 13-Jun-2025 Version 3 Page 1/11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Product Code(s) PZ03416
Trade Name: PZ03416
Not applicable

Chemical Family: Calcium channel blocker

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product for the treatment of high blood pressure (hypertension) angina

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045 1-800-879-3477 Pfizer Ireland Pharmaceuticals OSG Building

Ringaskiddy, Co. Cork.

Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Acute toxicity - OralCategory 4 - (H302)Reproductive toxicityCategory 1B - (H360D)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements



Signal word

Danger

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 2/11 Revision date 13-Jun-2025 Version 3

Hazard statements H302 - Harmful if swallowed

H360D - May damage the unborn child

Precautionary Statements - EU (§28, P201 - Obtain special instructions before use

1272/2008)

P202 - Do not handle until all safety precautions have been read and understood

P264 - Wash hands thoroughly after handling

P270 - Do not eat, drink or smoke when using this product P280 - Wear protective gloves and protective clothing

P301 + P312 - IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel

unwell

P330 - Rinse mouth

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and

international regulations as applicable

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

PBT & vPvB The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors.

This document has been prepared in accordance with standards for workplace safety, which Note:

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardaua

Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
orioniioai namo	VVOIGITE 70	registration	Index No)	according to	concentration	Wi i dotoi	(long-term)
		•	ilidex No)				(long-term)
		number		Regulation	limit (SCL)		
				(EC) No.			
				1272/2008			
				[CLP]			
Diltiazem	57		251-443-3	Acute Tox.4	Not classified	No data	No data
Hydrochloride				(H302)		available	available
(CAS #:				Repr.1B			
33286-22-5)				(H360D)			
NonHazardous							
Chemical name	Weight-%	REACH	EC No (EU	Classification	Specific	M-Factor	M-Factor
		registration	Index No)	according to	concentration		(long-term)
		number	,	Regulation	limit (SCL)		
				(EC) No.	()		
				1272/2008			

pira, Inc.)

Page 3/11

Version 3

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.) Revision date 13-Jun-2025

				[CLP]			
Mannitol	43	-	200-711-8	Not classified	Not classified	No data	No data
(CAS #: 69-65-8)						available	available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50	Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
		mg/kg	hour - dust/mist - mg/L	hour - vapor - mg/L	hour - gas - ppm
Diltiazem Hydrochloride 33286-22-5	560	271	No data available	No data available	No data available
Mannitol 69-65-8	13500	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. If not breathing, give artificial respiration.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 4/11 Revision date 13-Jun-2025 Version 3

Specific hazards arising from the

chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products

Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides, hydrogen chloride and other chlorine- and sulfur-containing compounds.

Explosion data

Sensitivity to mechanical impact No information available. No information available. Sensitivity to static discharge

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Personal precautions

Section 8). Minimize exposure.

Use personal protection recommended in Section 8. For emergency responders

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment

Prevent further leakage or spillage if safe to do so.

Methods for cleaning up

Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated

surface thoroughly.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections

See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. Avoid breathing

dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration

systems or other equivalent controls.

Handle in accordance with good industrial hygiene and safety practice. General hygiene considerations

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

Page 5/11 Version 3

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.) Revision date 13-Jun-2025

Trovidion date To dan 2020

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product for the treatment of. high blood pressure (hypertension).

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Diltiazem Hydrochloride

Pfizer OEL TWA-8 Hr: 70 µg/m³

Mannitol

Russia MAC: 10 mg/m³

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible

and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protectionUnder normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).

(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.).

Thermal hazards No information available.

Environmental exposure controls No information available.

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 6/11 Revision date 13-Jun-2025 Version 3

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance Lyophilized powder

Physical state Powder Color Off-white

Odor No information available.

No information available **Odor threshold**

Property <u>Values</u>

No data available Melting point / freezing point Boiling point or initial boiling point and boiling range No data available

Flammability (solid, gas) No data available Lower and upper explosion limit/flammability limit

Lower explosion limit No data available Upper explosion limit No data available No data available

Flash point No data available **Autoignition temperature**

Decomposition temperature

SADT (°C) No data available No data available No data available pH (as aqueous solution) Kinematic viscosity No data available **Dynamic viscosity** No data available Solubility No data available No data available Vapor pressure

Density and/or relative density No data available **Bulk density** No data available **Liquid Density** No data available No data available

Vapor density Particle characteristics

Particle Size No information available **Particle Size Distribution** No information available

9.2. Other information

Mixture Molecular formula Molecular weight Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available. Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 7/11 Revision date 13-Jun-2025 Version 3

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Short term May be harmful if swallowed (based on animal data) Drugs of this class have been

associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular

illnesses may be at increased risk from exposure.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Ingestion of this material may cause effects similar to those seen in clinical use including **Known Clinical Effects:**

dizziness, fatigue, hypotension (low blood pressure), edema and dyspnea.

Classification is based on mixture calculation methods based on component data **Acute toxicity**

Serious eye damage/eye irritation Based on available data, the classification criteria are not met. Skin corrosion/irritation Based on available data, the classification criteria are not met. Respiratory or skin sensitization Based on available data, the classification criteria are not met.

STOT - single exposure Based on available data, the classification criteria are not met. STOT - repeated exposure Based on available data, the classification criteria are not met.

Reproductive toxicity Classification is based on mixture calculation methods based on component data.

Germ cell mutagenicity Based on available data, the classification criteria are not met. Carcinogenicity Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. **Aspiration hazard**

Acute Toxicity: (Species, Route, End Point, Dose)

Diltiazem Hydrochloride

Rat Oral LD50 560 mg/kg

Rat Para-periosteal LD50 38 mg/kg Rat Subcutaneous LD50 520 mg/kg Mouse Oral LD50 508 mg/kg

Mouse Intravenous LD50 58 mg/kg

Mannitol

Rat Oral LD 50 13500 mg/kg Mouse Oral LD 50 22 g/kg

	Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
	Diltiazem Hydrochloride	= 560 mg/kg (Rat)	= 271 mg/kg (Rat)	-
Ī	Mannitol	= 13500 mg/kg (Rat)	-	-

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Diltiazem Hydrochloride

1 Month(s) Rat Oral 100 mg/kg/day NOAEL Liver, Blood, Heart

1 Month(s) Dog Oral 5 mg/kg/day NOAEL Kidney, Heart

6 Month(s) Dog Oral 10 mg/kg/day LOAEL Heart, Liver, Cardiovascular system

PZ03416

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 8/11 Revision date 13-Jun-2025 Version 3

1 Year(s) Dog Oral 5 mg/kg/day LOAEL Cardiovascular system, Heart

6 Month(s) Rat Oral 10 mg/kg/day NOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diltiazem Hydrochloride

Reproductive & Fertility Rat Oral 50 mg/kg/day NOAEL Fertility

Embryo / Fetal Development Mouse Oral 25 mg/kg/day LOAEL Embryotoxicity

Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Fetotoxicity

Embryo / Fetal Development Rabbit Intraperitoneal 6.3 mg/kg/day LOAEL Fetotoxicity, Teratogenic

Embryo / Fetal Development Rabbit Oral 17.5 mg/kg/day NOAEL Fetotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Diltiazem Hydrochloride

Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative

In Vivo Mammalian Cell Mutagenicity Negative In Vitro Mammalian Cell Mutagenicity Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diltiazem Hydrochloride

21 Month(s) Mouse Oral 30 mg/kg/day NOAEL Not carcinogenic

24 Month(s) Rat Oral 100 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or

OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should

be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

No information available. Mobility in soil

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 9/11 Revision date 13-Jun-2025 Version 3

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

Based on available data, the classification criteria are not met. PMT or vPvM properties

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Not applicable **UN number:** Not applicable UN proper shipping name: Not applicable Transport hazard class(es): Not applicable Packing group: **Environmental Hazard(s):** Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Diltiazem Hydrochloride

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Developmental **EINECS** 251-443-3

Mannitol

CERCLA/SARA Section 313 de minimus % Not Listed **California Proposition 65** Not Listed

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.)

Page 10 / 11 Revision date 13-Jun-2025 Version 3

TSCA Present 200-711-8 **EINECS AICS** Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905 Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable Not applicable Storage of Hazardous Material WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable **Major Accidents Ordinance SR 814.012** Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

No information available **Chemical Safety Report**

Product Name Diltiazem Hydrochloride for Injection (Hospira, Inc.) Revision date 13-Jun-2025

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H360D - May damage the unborn child

Data Sources: Pfizer proprietary drug development information.

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological

Information.

Revision date 13-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.